Skip to content
Home/Companies/Biotech/HyTest

HyTest

Biotech·Finland·Exited 2021·Held 3yr
Entry
2018
Hold
3yr
Exit
2021

Who owns HyTest?

HyTest is a Finnish Biotech company, now owned by Mindray, which acquired it in 2021 from Summa Equity.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Summa Equity
Investor
Summa Equity
Summa Equity Fund I · 2017 · Buyout

Key facts

HQFinland
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
Mindray
Exit Year
2021

More from Summa Equity Fund I

Other portfolio companies in the same fund.

Lakers Group
Exited 2021
IndustrialsSweden· 2018
to Vestum
LOGEX
Logex
Active
HealthTechNetherlands· 2018
Documaster
Exited 2025
SaaSNorway· 2017
to Main Capital Partners
Lin Education
Exited 2019
EdTechSweden· 2017
to Xllnc
Milarex
Exited 2025
FoodTechNorway· 2017
to Pangea
Norsk Gjenvinning
Active
Business ServicesNorway· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns HyTest?

HyTest is now owned by Mindray, which acquired it in 2021 from Summa Equity.

When did Mindray acquire HyTest?

Mindray acquired HyTest in 2021, buying from Summa Equity.

Who did HyTest sell to?

Summa Equity sold HyTest to Mindray in 2021 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue